Recombinant human anti-PD-1 monoclonal antibody(CSPC Zhongqi Pharma)

重组抗PD-1全人源单克隆抗体（石药集团中奇制药）

Report date: 2025/06/23 13:34:57

Base Information

Drug NameRecombinant human anti-PD-1 monoclonal antibody(CSPC Zhongqi Pharma)
Drug Alias Name重组抗PD-1全人源单克隆抗体注射液
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionProgrammed cell death protein 1 blockers
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungCarcinoma, Transitional Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesCSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesJushi Biopharmaceutical Co LtdCSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungCarcinoma, Transitional Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A